Renalytix PLC
LSE:RENX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.5
50.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Renalytix PLC
Renalytix PLC
Cash & Cash Equivalents
Renalytix PLC
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Renalytix PLC
LSE:RENX
|
Cash & Cash Equivalents
$24.7m
|
CAGR 3-Years
23%
|
CAGR 5-Years
259%
|
CAGR 10-Years
N/A
|
|
|
Craneware PLC
LSE:CRW
|
Cash & Cash Equivalents
$34.6m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
1%
|
|
|
Cambridge Cognition Holdings PLC
LSE:COG
|
Cash & Cash Equivalents
£3.4m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
|
Intelligent Ultrasound Group PLC
LSE:IUG
|
Cash & Cash Equivalents
£3m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
EMIS Group PLC
LSE:EMIS
|
Cash & Cash Equivalents
£48.5m
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Doctor Care Anywhere Group PLC
ASX:DOC
|
Cash & Cash Equivalents
£6.1m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
29%
|
CAGR 10-Years
N/A
|
|
Renalytix PLC
Glance View
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
See Also
What is Renalytix PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
24.7m
USD
Based on the financial report for Jun 30, 2023, Renalytix PLC's Cash & Cash Equivalents amounts to 24.7m USD.
What is Renalytix PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
259%
Over the last year, the Cash & Cash Equivalents growth was -40%. The average annual Cash & Cash Equivalents growth rates for Renalytix PLC have been 23% over the past three years , 259% over the past five years .
You don't have any saved screeners yet
